Fierce Biotech

Compass Therapeutics’ stock heads south after cancer bispecific misses on overall survival

Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Compass Therapeutics drops sharply as trial crossover complicates survival data in bile duct cancer patients

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...
Clinical Trials Arena on MSN

Compass Therapeutics’s stock crashes after OS miss in BTC trial

Compass Therapeutics will still submit tovecimig for approval despite the OS miss.

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus ...

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...